RU486 antagonizes the inhibitory action of progesterone on prostacyclin and thromboxane A2 synthesis in cultured rat myometrial explants.
A myometrial explant culture system was developed to investigate the effect of progesterone and the antiprogestagen RU486 on prostacyclin (PGI2) and thromboxane A2 (TXA2) synthesis by the rat myometrium. After culture, eicosanoid synthesis was stimulated with arachidonic acid (AA) and the calcium ionophore A23187 (A23187). Spontaneous release of eicosanoids was also studied. Progesterone inhibited the spontaneous release of PGI2 and TXA2 release by myometrial explants in a concentration- and time-dependent manner. Adequate inhibition of myometrial eicosanoid synthesis by physiological concentrations was achieved at 18 h of culture: all subsequent studies were carried out after an 18-h culture of explants. A23187- and AA-stimulated PGI2 and TXA2 synthesis were inhibited equipotently by progesterone. 17 beta-Estradiol alone was without effect on spontaneous AA- or A23187-stimulated PGI2 or TXA2 synthesis and was without effect on progesterone-elicited inhibition of eicosanoid synthesis in the myometrial explants. The protein synthesis inhibitors, actinomycin D and cycloheximide, did not block the inhibitory action of progesterone on A23187- or AA-stimulated eicosanoid synthesis by the myometrial explants and alone mimicked the inhibitory action of progesterone. The inhibitory action of progesterone on AA- and A23187-stimulated PGI2 and TXA2 synthesis was antagonized in a concentration-dependent manner by RU486. These data indicate that within this ex vivo system, progesterone probably inhibits myometrial cycloxygenase, that progesterone may exert this action through inhibition of a modulating or permissive protein, and that the antiprogestagen RU486 is an effective in vitro antagonist or progesterone.
D000818:Animals; D016718:Arachidonic Acid; D001095:Arachidonic Acids / Q000494:pharmacology; D000001:Calcimycin / Q000494:pharmacology; D046508:Culture Techniques; D003513:Cycloheximide / Q000494:pharmacology; D003609:Dactinomycin / Q000494:pharmacology; D011464:Epoprostenol / Q000096:biosynthesis*; D004963:Estrenes / Q000494:pharmacology*; D005260:Female; D015735:Mifepristone; D009215:Myometrium / Q000187:drug effects / Q000378:metabolism*; D011374:Progesterone / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D013928:Thromboxane A2 / Q000096:biosynthesis*
D001095:Arachidonic Acids; D004963:Estrenes; D003609:Dactinomycin; D016718:Arachidonic Acid; D015735:Mifepristone; D000001:Calcimycin; D011374:Progesterone; D013928:Thromboxane A2; D003513:Cycloheximide; D011464:Epoprostenol